Method of treating prostate cancer

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to oncology, and can be used for reduction of pain syndrome in prostate cancer. For this purpose catheter is installed into subarachnoid space between the fourth and fifth lumbar vertebrae; 5 ml of cerebrospinal fluid are sampled, mixed with suspension of 125 mg of hydrocortisone, mixture is incubated in thermostat for 30 minutes at temperature 37°C and introduced through the installed catheter 1 time per day with a day interval, without removing the catheter. Total number of mixture introductions is 5.

EFFECT: method makes it possible to realise complete course of medication treatment without development of side effects and improve life quality, relieving pain syndrome expression with reduction of amount of applied analgesics.

1 ex

 

The invention relates to medicine, in particular to cancer, and can be used in complex treatment of patients with malignant tumors of the prostate in the phase of gormonorezistentnost.

There is a method of treatment of malignant tumors of the prostate using complex anticancer chemotherapy multidirectional action. Connect them with previously taken by the blood of the patient, incubated and injected intravenously (Autohemotherapy in treatment of locally advanced or disseminated prostate cancer", you can discuss D.A., abstract of Diss. Kida. the honey. of Sciences, Rostov-on-don, 2002).

This method of treatment allows to reduce dysuric phenomena in patients to reduce the frequency of urination, difficulty and pain during urination, improve the General condition of patients, sleep and appetite.

However, the use of anticancer chemotherapy, United with Autocraft, for the treatment of patients with metastatic prostate cancer in the bones does not reduce pain in the bones, is not conducive to recovery of bone structures.

There is a method of treating prostate cancer with bone metastases by endolyumbalno introduction 2% oil solution sinestrola. When the needle is injected between 3-4 or 4-5 vertebrae of the lumbar spine, evacuate the cerebrospinal fluid in to the number 10, 20, 30, 40 and 50 ml and injected with 2% oil solution sinestrola equal to a remote amount of cerebrospinal fluid. Procedures for imposing sinestrola repeated at intervals of 5 days. The total dose rate sinestrola is 100-150 mg (Copyright certificate №1410324, "a Method for the treatment of generalized prostate cancer").

Authors suggest the introduction of sinestrola able to achieve a significant reduction in metastatic lesions, and in some cases almost completely eliminate metastases in the pelvic bones and lungs, improve the flow of urine.

However sinestrol is cardiotoksicnae drug and necessitates the use of additional drugs that enhance the activity of the cardiovascular system. Not without flaws, and method of administration sinestrola. The need for each application to produce a new puncture between the spinous processes of the vertebrae causing additional pain to the patient.

The aim of the invention is to improve the direct and immediate results of medical treatment of prostate cancer.

The goal is to reach the fact that in the subarachnoid space between the fourth and fifth lumbar vertebrae catheter and taking 5 ml of cerebrospinal fluid, mix it with suspension 125 mg hydrocortisone, incubi the comfort in thermostat for 30 minutes at 37°C and injected through the installed catheter 1 times a day at intervals through the day, without removing the catheter. The total number of injections of hydrocortisone - 5.

Comparative analysis of the known methods of treatment of prostate cancer and claimed enables us to establish the novelty and difference of the latter.

The novelty of the developed method of treatment of prostate cancer" is the method of administration of the medicinal product, providing multiple and painless penetration into the subarachnoid space. This allows the installed catheter.

In open sources information of Russia, CIS and abroad similar "treatment of prostate cancer" could not be found.

The claimed "a Method for the treatment of prostate cancer" is industrially applicable. It can be reproduced and repeated many times in the specialized Oncology institutions.

The method is as follows. The patient catheter in the subarachnoid space between the fourth and fifth lumbar vertebrae. Make the fence 5 ml of cerebrospinal fluid, mix it with suspension 125 mg hydrocortisone, placed in a thermostat, incubated for 30 minutes at 37°C and injected through the catheter. Therapeutic measures are carried out once a day, at intervals through the day without removing the catheter. The total number of introductions of hydrocortisone - 5.

A specific example with the person can serve as an extract from the history.

Patient C., born in 1949, case history No. with-9506/Yu admitted to the urology Department of RNII 01.07.2009, with a diagnosis of prostate Cancer T3NXM1b (multiple mts dice, mts to retroperitoneal l/u), Cllr. Pain in the bones (the patient walked only with the aid of a cane; he took large doses of Energetikov).

Treated about the underlying disease since 2007, histological analysis No. 976613-624 - dark-cell acinar usernotification adenocarcinoma. 03.07.09 performed osteointegrated. Revealed multiple metastases in the bones of the skeleton: the seventh cervical vertebra; the sixth, eighth and twelfth thoracic vertebrae; the second lumbar vertebra; in the right wing of the Ilium; in the fifth and sixth ribs on the left.

06.07.09 patient in the subarachnoid space between the fourth and fifth lumbar vertebrae installed catheter. Extracted with 5 ml of cerebrospinal fluid, the latter connected with 125 mg suspension hydrocortisone. The mixture is incubated in the incubator for 30 minutes at 37°C and introduced into the installed catheter. Therapeutic measures are carried out five times a day.

20.07.09 the patient was discharged from hospital in satisfactory condition. Pain disappeared, improved General condition. The patient is active. Walking without the aid of a cane.

Technical and economic efficiency of the proposed Method l the treatment of prostate cancer" is possible:

- to carry out full course of medical treatment without adverse negative effects;

to reduce the intensity of pain syndrome and significantly reduce the number primeneniya of Energetikov;

- to improve the quality of life.

Method of reducing pain in cancer of the prostate, including the introduction of anticancer chemotherapy, characterized in that the patient into the subarachnoid space between the fourth and fifth lumbar vertebrae set the catheter; produce fence 5 ml of cerebrospinal fluid, mix it with suspension 125 mg hydrocortisone, incubate the mixture in the incubator for 30 min at 37°C and injected through the installed catheter 1 times a day at intervals through the day without removing the catheter, the total number of injections of the mixture - 5.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and deals with composition, which contains salt of "п"-tolyolsulfonic acid of methylamide 4 {4-[3 -(4-chlor-3-tri-fluoromethylphenyl)-ureido]-phenoxypyridin-2-carbonic acid as active substance in amount not less than 55% of composition weight, and at least one pharmaceutically acceptable carrier. Invention also relates to application of said composition for treatment of hyperproliferative diseases such as cancer.

EFFECT: composition possesses high stability in storing, and possesses high bioaccessability.

16 cl, 2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is application of inhibitor of hystondeacetylase (HDAL) N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propene amide for production of medication for treating myeloma and corresponding method of treatment.

EFFECT: claimed substance demonstrates activity with respect to cell lines of myeloma in very low nanomolecular range, from 50 nM in contrast to earlier known HDAC inhibitors.

7 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used in treatment of malignant retroperitoneal tumours in children and teenagers. Method is realised in the following way. In younger children from 3 months to 12 years blood is sampled from cubital vein in amount not more than 5% of circulating blood volume for one introduction of chemical preparation, in teenagers and younger people in amount 200 ml. 2-4 courses of induction autohemochemical therapy are carried out, chemical preparations are introduced taking into account tumour stage and in recommended doses, after which local therapy on primary nidus is carried out - surgical and/or radio treatment. Then, consolidation by autohemochemical therapy with application of chemical preparations of the second line is carried out.

EFFECT: application of invention makes it possible to increase treatment efficiency due to reduction of the size of tumour and metastatic niduses, and reduction of toxica effects of chemical preparations.

2 ex

FIELD: food industry.

SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course.

EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient.

36 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula (I) or to their salts:

,

where: R1 or R2, independently represents a group consisting of R1, R2, N and/or O selected from the groups:

,

Z1 represents hydrogen or hydroxyl; Z2 represents hydrogen or hydroxyl; Z3 represents C6-C10aryl; Z4 represents C1-C6alkoxy. The invention also refers to a method for producing the compounds according to any of claims 1-4, as well as to application of the compounds.

EFFECT: preparation of new biologically active compounds which exhibit anticancer activity.

12 cl, 10 ex, 3 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds (la) of formula applied as tyrosine kinase c-Met inhibitors. , where: LA is selected from ,

or ; RA is selected from:

or each RA2 and RA6 represents hydrogen; RA3 represents RAr; or RA3, RA4 and carbon atoms whereto attached form 6-members aryl, optionally substituted, in the amount up to 4 by independent groups RAr, or a 5-6-members heterocyclyl or heteroaryl ring containing at least one O, N or S atom; R represents -OH; RA5 represents hydrogen or RAr; LB represents a covalent bond or -N(R*)-; RB represents halogen, NH2 or C1-8aliphatic group, optionally substituted by R; a 6-10-members aryl ring; a 3-7-members carbocyclyl ring, a 5-10-members heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen and sulphur atoms, where each said aryl or heteroaryl ring is optionally substituted, in the amount up to five by independent groups RAr; R represents halogen, -R°, -SR°, Ph, optionally substituted R° or -C(O)OR°; each RAr is independently selected from halogen, -R°, -OR°, -SR°, Ph, optionally substituted in the amount up to five by independent groups -R°, -CN, -N(R°)2 or -C(O)OR°; or two adjacent groups RAr taken together, represent 1,2-methylenedixy or 1,2-ethylenedixy; each R* represents hydrogen; and each R° represents independently hydrogen, an optionally substituted C1-6aliphatic radical or an unsubstituted 5-6-members heteroaryl or heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulphur atoms.

EFFECT: invention refers to pharmaceutically acceptable compositions containing the compounds under the invention, and methods of application of the compositions in treatment of various proliferative disorders.

10 cl, 4 tbl, 548 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: there is described new macrocyclic compound of general formula 1-c:

and its pharmaceutically acceptable acid or base addition salts or its stereoisomers (the radical values are presented in the patent claim).

EFFECT: producing the compounds which are hepatitis type C virus inhibitors and can find application in medicine.

9 cl, 1 tbl, 95 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a new acid dihydrogenphosphate of 2-(3-{6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidine-4-yl}phenyl)-2-methylpropionic acid of formula optionally in a crystalline form exhibiting cAMP inhibitor properties. Also, the invention refers to a pharmaceutical composition.

EFFECT: compound can find application for treating the diseases associated with cell expression of prostaglandin D2 in such diseases, as allergic rhinitis, bronchial asthma, allergic conjunctivitis, etc.

3 cl, 12 dwg, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula which exhibits an inhibiting action on protein kinases A and B. In the compounds of formula (I), A represents a saturated hydrocarbon binding group containing 1 to 7 carbon atom where the binding group includes a chain of the maximum length 5 atoms located between R1 and NR2R3, and a chain of the maximum length 4 atoms located between E and NR2R3 where one of carbon atoms in the binding group can be optionally substituted by an oxygen or nitrogen atom; and where the carbon atoms of the binding group A can optionally have one or more substitutes selected from oxo, fluorine and hydroxy provided the hydroxy group if any is not located on a carbon α-atom in relation to the NR2R3 group and provided the oxo group if any is located on the carbon α-atom in relation to the NR2R3; E represents a phenyl or pyridine group; R1 represents a C6-10aryl or pyridyl group which is not substituted or substituted with 1 or 2 substitutes specified in the patent claim; and R2, R3, R4 and R5 have the values specified in the points of the patent claim.

EFFECT: invention refers to a pharmaceutical composition containing said compounds, to methods of making the compounds and their application as cancer drugs.

29 cl, 1 tbl, 108 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of general formula

where there are R3/R3', R4/R4' and R5/R5' where at least one of either R4/R4' or R5/R5' always represents a fluorine atom, and the other radical values are disclosed in the description.

EFFECT: making the compounds which are γ-secretase inhibitors, and can be effective in treating Alzheimer's disease or advanced cancers, including but not limited to carcinoma of uterine cervix and breast carcinoma and malignant tumours of hematopoietic system.

15 cl, 3 tbl, 18 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, can be applied in resuscitation science, surgery, clinical immunology. For correction of immune insufficiency in patients with mechanical jaundice of non-tumour genesis in addition to complex traditional therapy of post-operational period from the first day after operation one time per day intravenously introduced is 1 ml of 1%-solution of glutoxim on autoblood, with its preliminary 30 minute incubation with 20 ml of autoblood. Treatment course is 5 sessions.

EFFECT: method makes it possible to increase treatment efficiency, reduce lethality, reduce duration of patient's presence in hospital.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: blood product filtration through filter, filled with carrier, covered with polymer, is performed. Said polymer is formed by three elements: element derived from hydrophobic polymerised monomer, element, derived from polymerised monomer, which contains main nitrogen-containing part, and element, derived from polymerised monomer, which contains proton neutral hydrophilic part as balance. After filtration collection of blood product is carried out. Efficiency of pathologic prion protein removal constitutes from 1.2 to 4.1 and higher.

EFFECT: efficient removal of pathologic prion protein from blood product with simultaneous removal of leukocytes.

12 cl, 1 dwg, 1 tbl, 23 ex

FIELD: medicine.

SUBSTANCE: sampling of blood from patient's ulnar vein with first and second syringe-test-tubes is carried out. First syringe-test-tube is centrifuged with acceleration 250 g for 10 minutes. Formed plasma and coagulated blood in second syringe-test-tube are centrifuged with acceleration 1000 g for 10 minutes. Platelet-poor plasma is separated from platelet-enriched plasma. Activator of platelet-enriched plasma is prepared from supernatant fluid after centrifugation of coagulated blood and platelet-poor plasma, with weight ratio in fractions: 1:1, and 10% calcium chloride solution. The latter - in drop manner, mixing until required mixture concentration is obtained. Platelet-enriched plasma is mixed with activator with weight ratio in fractions 1:3 respectively.

EFFECT: application of method allows to realise more complete isolation of platelets from sampled blood, which increases efficiency, physiologicity and safety of obtained plasma.

2 cl

FIELD: medicine.

SUBSTANCE: system includes a kit of disposable elements for transportation of liquid, which are preliminarily connected or include aseptic connectors for creation of connections between them in aseptic way, or are adapted for being aseptically connected. Kit includes three sets of disposable sterile elements: set for collection, set for processing and set for transplantation, packed in blister packing on carrier, such as tray, which has one department, containing each connected with other set of said kit. System can be applied for obtaining platelet concentrate for separate application. Method of collection and processing of cell subpopulation includes collection of isolated cells in collection chamber, connected with isolation device, processing of cells in centrifugal operation chamber, which is the same chamber as the chamber for collection, or which is connected with collection chamber, and collection of processed cells in chamber for reinfusion, which also is the same chamber as the operation chamber, or which is connected with operation chamber, and delivery of processed cell subpopulations back to the patient.

EFFECT: application of invention makes it possible to ensure automatic processing in closed system in on-line mode.

17 cl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used in treating patients with secondary lymphedema of upper extremities. That is ensured by the introduction of autolymphocytes extracorporally processed with Roncoleukin and dissolved in normal saline in subcutaneous fat of an injured extremity in a projection of lymph node basins along a medial and lateral surface of forearm. The solution is introduced in 20 points by 0.5 ml containing 20 to 30 million cells per each point on the average. The procedures are thrice-repeated every 72 hours.

EFFECT: method allows to intensify lymphatic outflow from the injured extremity, to reduce paravasal inflammations of subcutaneous fat due to stimulating cell components of the immune system.

8 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves the intravenous and/or intramuscular introduction of the drugs used in myelopathy, balneotherapy in the form of baths. Acupressure and manual therapy are applied in addition. The manual therapy requires such techniques, as ischemic compression, release phenomenon, fascial broach, postisometric relaxation of the muscles involved in a pathological process. Discontinuous therapeutic plasmapheresis is applied with using either Baxter, or Bekman, or Haemophoenix apparatuses, and/or extracorporal ultraviolet blood irradiations is ensured by the apparatus Isolda MD 73 M. The apparatus Cryo-Jet is used for cryotherapy with cooled dry air at the level of degenerative dystrophic changed vertebral motor cervical segments and muscle attachment points.

EFFECT: method improves clinical effectiveness due to fast pain management, enlarged range of active and passive motions, normalised muscular tonus, increased muscular strength and corrected vegetovascular disorders.

6 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, and can be used for treatment of malignant lung neoplasms in experiment. For this purpose performed is extracorporal irradiation of autoblood with red incoherent light λ=0.67 mcm dose W=3.06 J/cm2 in continuous mode with exposition duration to three minutes. After that 15-20 minutes later into said blood added is cyclophosphane in dose 40 mg/kg and the mixture is incubated for 40 minutes at T=37°C. After that it is re-infused into subclavian vein of the animal.

EFFECT: claimed method allows to reduce terms of anti-tumour treatment, increase efficiency of cyclophosphane action, reduce its toxic manifestations, increase animals' life term, increase non-specific anti-tumour resistance, activate anti stressor mechanisms.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynecology and concerns the integrated treatment of tuboperitoneal infertility. That is ensured by low-intensity infrared lasing at power 150 Wt, wave length 0.89 mcm of the inguinal lymph nodes and a skin projection of the lumbosacral plexus. The exposure time is 1 min for each region for 1st session. Thereafter, the exposure time is increased to 3 minutes during 10 sessions. It is combined with local intraendometrial introduction of an antibacterial agent and an immunomodulator. Besides the treatment involves a number of plasmapheresis sessions and introduction of nonsteroidal anti-inflammatory drugs, antioxidants, desensitisers, and vaginal sanitation.

EFFECT: method provides effective restoration of menstruation and reproductive function.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery and intensive therapy, and can be used in treating endotoxicoses caused by septic conditions. That is ensured by removal of a destruction area to be thereafter sanitised and drained. It is followed with lymphostimulating therapy by introduction of 0.25% Novocaine 60 ml with dissolved 0.1 g of Lydase and 1.0 ml of Pentoxifylline into the interspinous spaces in number of 1-3 injections. Further, discrete plasmapheresis in amount 400 ml for severe patients and 800 ml in moderate patients is applied in number of 1-8 procedures. The lymphostimulating therapy is alternated every second day with lymphotropic extracorporal pharmacoimmunotherapy with using a medicated mixture prepared by incubation of 40-60 ml of the patient's plasma with received plasma of the patient with Roncoleukin in dosage 500-1 million UN and Cefabol in dosage 1 g for 45 min at 37°C. In peritonitis and peritoneal sepsis, the medicated mixture is introduced in the bolus form in the retroperitoneal fat. The destructive processes in the pleural cavity require introduction of said mixture in the axillary cavity.

EFFECT: method provides endotoxin weakening in the bloodstream, intertissue spaces and cavities due to combined multidirectional local and system effect on the lymphoid system.

3 cl, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatology, and can be used for treating patients with psoriasis. Method includes drug therapy with application of hyposensibilising anti-histamine medications, hepatoprotectors, vitamins, local exfoliating and releasing ointments, general ultraviolet oirradiation. Method also includes plasmapheresis with division of blood into plasma and erythrocyte mass by centrifugation with removal of patient's plasma and erythrocyte mass reinfusion. Before returning erythrocyte mass into patient's organism it is processed with 200 ml of ozonised physiological solution with ozone concentration 2.5 mg/l. After that reinfusion of ozonised erythrocyte mass is carried out.

EFFECT: method allows to increase efficiency of psoriasis treatment due to reduction of PASI index level, correction of disturbed indices of hemostasis and lipid exchange.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to neurology, and deals with Parkinsonism treatment. For this purpose, performed are injections of 0.5% Novocain solution in amount 10.0 ml with addition of 20 mg of hydrocortisone suspension in one syringe hypodermically paravertebrally at the level of 4 and 6 cervical vertebrae with 3 day interval. Course includes three injections.

EFFECT: method ensures tremor reduction and improvement of movement coordination due to reflex impact via cervical spinal nerves on neuromediator and receptor systems of brain stem and subcortical structures.

1 ex

Up!